Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China

Journal of Infection

Volumn 61, Issue 2, 2010, Pages 150-154

  Yin, Xiaomao ^a   Yu, Zhaoxian ^a  

^a GUANGZHOU CHEST HOSPITAL   (China)

Author keywords

GyrA; GyrB; Levofloxacin; Mycobacterium tuberculosis

Indexed keywords

BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); OFLOXACIN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; ADOLESCENT; CHEMISTRY; CHINA; DNA SEQUENCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHINA; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, PULMONARY; YOUNG ADULT; LEVOFLOXACIN;

EID: 77955050834     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.05.001     Document Type: Article

References (34)

1. Feuerriegel S., Cox H.S., Zarkua N., Karimovich H.A., Braker K., Rusch-Gerdes S., et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009, 53:3353-3356.
2. Andersson M.I., MacGowan A.P. Development of the quinolones. J of Antimicrob Chemother 2003, 51(Suppl. 1):1-11.
3. Emmerson A.M., Jones A.M. The quinolones: decades of development and use. J Antimicrob Chemother 2003, 51(Suppl. 1):13-20.
4. Wang J.Y., Lee L.N., Lai H.C., Wang S.K., Jan I.S., Yu C.J., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
5. Mohanty K.C., Dhamgaye T.M. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993, 104:1194-1198.
6. Sirgel F.A., Botha F.J., Parkin D.P., Van de wal B.W., Schall R., Donald P.R., et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997, 156:901-905.
7. Vacher S., Pellegrin J.L., Leblanc F., Fourche J., Maugein J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother 1999, 44:847-852.
8. Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007, 51:576-582.
9. Akcali S., Surucuoglu S., Cicek C., Ozbakkaloglu B. In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium Tuberculosis. Ann Saudi Med 2005, 25:409-412.
10. Piersimoni C., Lacchini C., Penati V., Iona E., Fattorini L., Nista D., et al. Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxaxin. Diagn Microbiol Infect Dis 2007, 57:283-287.
11. Sun Z., Zhang J., Zhang X., Wang S., Zhang Y., Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008, 31:115-121.
12. Peloquin C.A., Hadad D.J., Molino L.P., Palaci M., Boom W.H., Dietze R., et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:852-857.
13. Xu P., Li X., Zhao M., Gui X., DeRiemer K., Gagneux S., et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009, 53:3170-3172.
14. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003, 51:1109-1117.
15. Aubry A., Veziris N., Cambau E., Truffo-Perrot C., Jariler V., Fisher L.M. Novel gyrase mutations in quinolone and - hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2008, 50:104-112.
16. Chu D.T., Fernandes P.B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Cheomther 1989, 33:131-135.
17. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61:377-392.
18. Hooper D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000, 31(Suppl. 2):S24-S28.
19. Hawkey P.M. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003, 51(Suppl. 1):29-35.
20. Chen F.J., Lo H.J. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 2003, 36:1-9.
21. Morgan-Linnell S.K., Becnel Boyd L., Steffen D., Zenchiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53:235-241.
22. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994, 38:773-780.
23. Guillemin I., Jarlier V., Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998, 42:2084-2088.
24. Shi R., Zhang J., Li C., Kazumi Y., Sugawara I. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006, 44:4566-4568.
25. Chan R.C., Hui M., Chan E.W., Au T.K., Chin M.L., Yip C.K., et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007, 59:866-873.
26. Umubyeyi A.N., Rigouts L., Shamputa I.C., Fissette K., de Rijk P.W., Strulens M.J., et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007, 59:1031-1033.
27. Mokrousov I., Otten T., Manichva O., Potapova Y., Vishnevsky B., Narvskaya O., et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008, 52:2937-2939.
28. Ball P. Quinolone generations: natural history or natural selection?. J Antimicrob Chemother 2000, 46(Suppl. 3):17-24.
29. Yew W.W., Chan C.K., Chau C.H., Tam C.M., Leung C.C., Wong P.C., et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000, 117:744-751.
30. Yew W.W., Chan C.K., Leung C.C., Chau C.H., Tam C.M., Wong P.C., et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003, 124:1476-1481.
31. Marrra F., Marra C.A., Moadebi S., Shi P., Elwood R.K., Stark G., et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005, 128:1406-1413.
32. Huang T.S., Kunin C.M., Shin-Jung Lee S., Chen Y.S., Tu H.Z., Liu Y.C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
33. Siddiqi N., Shamim M., Hussain S., Choudhary K.R., Ahmed N., Prachee, et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from Patients in North India. Antimicrob Agents Chemother 2002, 46:443-450.
34. Matrat S., Veziris N., Mayer C., Jarlier V., Truffot-Permot C., Camuset J., et al. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 2008, 50:4170-4173.